New da­ta show Bio­Mar­in's trou­bled he­mo­phil­ia gene ther­a­py con­tin­ues to fade, open­ing room for ri­vals

The ef­fects of Bio­Marin’s vaunt­ed gene ther­a­py for he­mo­phil­ia A are con­tin­u­ing to fade in the ear­li­est treat­ed pa­tients, re­new­ing ques­tions about the long-term prospects …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER